- Home
- ANL vs COEP Comparison
ANL vs COEP Comparison
Compare ANL & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANL | COEP |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.0M | 100.4M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANL | COEP |
|---|---|---|
| Price | $1.35 | $15.50 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 28.5K | ★ 91.6K |
| Earning Date | 04-20-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,996.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.88 | $2.31 |
| 52 Week High | $2.99 | $21.41 |
Technical Indicators
Market Signals| Indicator | ANL | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 51.04 | 45.46 |
| Support Level | $0.88 | $14.82 |
| Resistance Level | $1.59 | $16.45 |
| Average True Range (ATR) | 0.18 | 1.47 |
| MACD | 0.00 | -0.21 |
| Stochastic Oscillator | 70.48 | 4.78 |
Price Performance
Historical ComparisonAbout ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.